VOL. I · ISSUE 01 
LIVE · 166 PROFILESSEARCH →
PeptaHub
The comprehensive peptide reference
RECOVERY32 READER REPORTS4.1

TB-500

Also known as Thymosin Beta-4, Tβ4

TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring 43-amino-acid peptide found in nearly all human tissues. It promotes cell migration, wound healing, and anti-inflammatory responses. Often used in combination with BPC-157 for injury recovery protocols.

§ 01

Overview

TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring 43-amino-acid peptide found in nearly all human tissues. It promotes cell migration, wound healing, and anti-inflammatory responses. Often used in combination with BPC-157 for injury recovery protocols.

§ 02

Mechanism of action

TB-500 upregulates actin, a cell-building protein essential for cell migration and tissue repair. It promotes angiogenesis, reduces inflammation by downregulating inflammatory cytokines, and has demonstrated cardioprotective effects in animal models by reducing scar formation after cardiac injury.

§ 03

Dosing protocols

PurposeRouteDosageFrequency
injury recoverysubcutaneous25 mgtwice weekly

Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.

§ 04

Research summary

Preclinical studies show accelerated wound healing, reduced cardiac scar tissue, and improved neurological recovery after brain injury. Used extensively in veterinary medicine (particularly racehorses). Limited human clinical data; most evidence comes from animal studies and case reports.

§ 05

Side effects

Headache
Nausea
Injection site pain
Lethargy
Head rush

Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.

§ 06

Common stacks

Peptides commonly paired with TB-500 for synergistic effects.

§ 08

Where to get it

Verified directory — coming soon

PeptaHub is building a verified supplier directory with third-party testing data, compliance status, and reader ratings. Supplier listings will be available if FDA reclassification is formalized.